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Background: CDK11p58, a Ser/Thr kinase that belongs to the cell division cycle 2-like 1 (CDC2L1) subfamily, is associated
with cell cycle progression, tumorigenesis and apoptotic signaling. CDK11p58 is also involved in the regulation of steroid
receptors, such as androgen and estrogen receptors. We previously found that CDK11p58 was abnormally expressed in
prostate cancer. However, its role in breast cancer remains unclear.
Methods: CDK11p58 expression was evaluated by immunohistochemical staining in a tissue array. A Transwell
assay was used to detect invasion and metastasis in breast cancer cells. The TaqMan® Metastasis Gene
Expression Assay was used to search for potential downstream factors in the CDK11p58 signaling pathway.
qRT-PCR was used to evaluate mRNA levels, and the dual luciferase array was used to analyze promoter activity.
Western blotting was used to detect the protein level.
Results: CDK11p58 expression was negatively correlated with node status (P = 0.012), relapse status (P = 0.002)
and metastasis status (P = 0.023). Kaplan-Meier survival curves indicated that the disease-free survival (DFS) was
significantly poor in breast cancer patients with low CDK11 expression. Interestingly, using the breast cancer cell
lines ZR-75-30 and MDA-MB-231, we found that CDK11p58 was capable of repressing the migration and invasion
of ERα-positive breast cancer cells, but not ERα-negative breast cancer cells, in a kinase-dependent manner. Gene
expression assays demonstrated that integrin β3 mRNA was dramatically repressed by CDK11p58, and luciferase
results confirmed that the integrin β3 promoter was inhibited by CDK11p58 through ERα repression. The expression
of integrin β3 was highly related to ERα signaling; ERα overexpression stimulated integrin β3 expression, whereas
siRNA-mediated knockdown of ERα attenuated integrin β3 expression.
Conclusions: These data indicate that CDK11p58 is an anti-metastatic gene in ERα-positive breast cancer and that
the regulation of integrin β3 by CDK11p58 via the repression of ERα signaling may constitute part of a signaling
pathway underlying breast cancer invasion.
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Breast cancer is the most common malignancy among
women and represents an important public health issue [1].
It is the major cause of cancer-related death in women, and
treatment is particularly difficult in patients with tumor
metastasis [2]. Despite recent improvements in survival
rates, many patients relapse, and the majority of these pa-
tients die from disseminated metastatic disease [3].
The chromosome 1p36 locus is frequently mutated in
many types of human tumors, especially in breast tumors.
This lesion is associated with progression and lymph node
metastasis [4], poor prognosis [5], higher rate of recur-
rence [6], large tumor size and DNA aneuploidy [7]. Dele-
tion of this chromosome region occurs late in oncogenesis
and is correlated with aggressive tumor growth, suggesting
that one or more tumor-related genes may reside in this
region [8]. However, no specific tumor suppressor gene at
1p36 has yet been identified. Previous studies have identi-
fied CHD5 [9] and KIF1B [10] as candidate tumor sup-
pressor genes in this region, and more recently it was
reported that disruption of PER3 function may indicate
the likelihood of tumor recurrence in patients with ERα-
positive tumors [11]. However, to date, no specific roles
for these genes in breast cancer development have been
demonstrated.
CDK11p58 belongs to the large family of p34cdc2-
related kinases [12] and is located on human chromo-
some 1p36.33, a region frequently mutated in numerous
human tumors, including breast cancer. CDK11p58 is
specifically expressed in the G2/M phase, and expres-
sion is closely associated with cell cycle arrest, oncogen-
esis and apoptosis [13,14]. Centrosome abnormalities are a
common feature of breast cancer [15,16]. The overexpres-
sion of centrosome-related genes has been detected in
premalignant lesions, in situ breast tumors and over 70%
of invasive breast tumors, and is associated with aneu-
ploidy and tumor development [17]. CDK11p58 is a
centrosome-associated mitotic kinase involved in centro-
some maturation and bipolar spindle formation [18] and
is required for centriole duplication and Plk4 recruitment
to mitotic centrosomes [19]. Furthermore, we found that
Thr-370 in CDK11p58 is required for its autophosphoryl-
ation, dimerization and kinase activity [13].
Previous studies have shown that CDK11p58 is involved
in the negative regulation of steroid receptors in a kinase
activity-dependent manner, including androgen [20], vita-
min D [21] and estrogen receptors (ERs) [22]. We previ-
ously demonstrated that CDK11p58 promotes the ubiquitin/
proteasome-mediated degradation of ERα to repress its
transcriptional activity [22]. The sex steroid estrogen plays
a major role in the development and progression of breast
cancer and promotes breast cancer proliferation through a
number of established pathways [23]. Estrogen promotes
breast cancer cell motility and invasion in ERα-positivebreast cancer cells, largely through ERα via FAK and N-
WASP [24]. Additionally, the estrogen-ERα complex stimu-
lates the transcriptional activity of MMP-26 and contributes
to the survival of ERα-positive breast cancer patients [25].
Because CDK11p58 is involved in the negative regulation
of the ERα signaling pathway, we speculated whether
CDK11p58 may function as a tumor suppressor in breast
cancer via the inhibition of ERα.
In this study, we demonstrate that CDK11p58 inhibited the
invasion of ERα-positive breast cancer cells by downregulat-
ing integrin β3 expression via ERα signaling. Moreover, the
functions of CDK11p58 were highly dependent on its kinase
activity. These data indicate that CDK11p58 plays an import-
ant role in the negative regulation of breast cancer invasion.
Methods
Patient samples
RNALater-preserved solid tissues, formalin-fixed, paraffin-
embedded (FFPE) breast cancer tissues and adjacent nor-
mal tissue (ANCT) were obtained from Fudan University
Shanghai Cancer Center between 2002 and 2004. The tu-
mors were assessed according to the WHO classifica-
tion by two academic pathologists. This study was
approved by the Ethics Committee of Fudan University
Shanghai Cancer Center for Clinical Research. Written
informed consent was obtained from all patients.
Immunohistochemical (IHC) analysis
A total of 250 FFPE blocks of breast cancer tissues and
ANCT were collected for tissue microarrays. Two breast
cancer tissue cores and two ANCT cores from the same
patient’s FFPE blocks were arranged on a recipient paraffin
block (with a 1-mm core per specimen). Paraffin sections
(3-μm thick) were deparaffinized in xylene and rehydrated
in a graded alcohol series, boiled with 10 mmol/L of cit-
rate buffer (pH 6) for 15 min and pre-incubated in block-
ing solution (10% normal goat sera) for 1 h at room
temperature. The steps were performed using the Envision
two-step method. The Envision and DAB Color Kit was
purchased from Gene Tech Company Limited (Shanghai,
China). A rabbit anti-human polyclonal antibody against
CDK11 was used at a 1:100 dilution. PBS (phosphate buff-
ered saline) was used as a negative control. The tissue
microarray slides were concurrently evaluated by two of
the authors. Granular nuclear staining was assessed as
positive. The staining index (SI, range 0–9) was considered
as the product of the intensity score (0, no staining; 1+,
faint/equivocal; 2+, moderate; 3+, strong) and the distri-
bution score (0, no staining; 1+, staining of <10% of
cells; 2+, between 10% and 50% of cells; and 3+, >50% of
cells). For CDK11 protein in this study, a moderate/
strong cytoplasm staining (SI = 3–9) was defined as
positive staining, and a weak or negative staining (SI =
0–2) was defined as negative staining.
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MCF-7, MDA-MB-231, ZR-75-30 and 293 T cells were
grown using RPMI1640 supplemented with 10% fetal bo-
vine serum (FBS), 100 units/ml penicillin and 100 μg/ml
streptomycin (Cat. 10378-016, Invitrogen, USA) at 37°C
and 5% CO2. The constructions of CDK11
p58 mutant
plasmids T370A and T370D were mentioned in ourFigure 1 Immunohistochemistry of CDK11 in tissue microarrays. (A) C
(1) (2) low expression, (3) (4) high expression. All immunohistochemical ph
expression and disease free survival (DFS)/overall survival (OS). P values weprevious report [13]. Cell transfection was performed
with Lipofectamine 2000 transfection reagent (Cat. 11668-
019, Invitrogen) according to the manufacturer’s instructions.
RNA interference
Small interfering RNAs (siRNA) designed for CDK11
(three siRNAs, siRNA1–3) and ERα (siERα) were orderedDK11 immunostaining was determined in breast cancer and scored as
otomicrographs are magnified 400×. (B) Relationship between CDK11
re calculated using the unadjusted log-rank test.
Table 1 Relationship between CDK11p58 expression and
clinicopathological features in breast cancer patients
Characteristics CDK11p58
Low High n x2 p
Age(years) 7.024 0.008
<50 27(8.1%) 78(31.5%) 105
≥50 18(7.3%) 125(50.4%) 143
Menopausal status 0.375 0.540
Pre 29(11.6%) 122(48.8%) 151
Post 16(6.4%) 83(33.2%) 99
Tumor size (cm) 0.939 0.333
≦2 cm 18(7.4%) 95(39.1%) 113
>2 cm 27(11.1%) 103(42.4%) 130
Node status 6.312 0.012
Negative 18(7.2%) 124(49.6%) 142
Positive 27(10.8%) 81(32.4%) 108
ER status 4.065 0.044
Negative 33(13.2) 117(46.8%) 150
Positive 12(4.8%) 88(35.2) 100
HER-2 status 2.823 0.093
Negative 22(8.8%) 128(51.2%) 150
Positive 23(9.2%) 77(30.8) 100
Differentiation 1.456 0.228
III 26(13.7%) 142(74.7%) 130
III 14(7.4%) 49(25.8%) 60
TNM stage 1.567 0.211
III 23(11%) 129(61.4%) 152
III 13(6.2%) 45(21.4%) 58
Relapse 9.323 0.002
No 29(11.8%) 179(72.8%) 208
Yes 13(5.3%) 25(10.2%) 38
Metastasis 4.803 0.023
No 26(10.6%) 159(64.6%) 185
Yes 16(6.5%) 45(18.3%) 61
Statistically significant p < 0.05 are indicated in bold. ER, estrogen receptor;
PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2.
Chi et al. BMC Cancer 2014, 14:577 Page 4 of 10
http://www.biomedcentral.com/1471-2407/14/577from Shanghai GenePharma Co., Ltd. The sequences of
the three siRNAs for siCDK11 were as follows: siRNA1,
5′-GAAGCAUGCUAGAGUGAAATT-3′, siRNA2, 5′-G
GGAAUGGGAAAGACAGAATT-3′, and siRNA3, 5′-GC
AGCAACAUGGACAAGAUTT-3′. The siERα sequence
was 5′-GGAGAAUGUUGAAGCACAATT-3′.
Transwell invasion
Cell invasion was assayed using BD BioCoat Growth Fac-
tor Reduced (GFR) Matrigel Invasion Chambers (BD, CA).
Transfected ZR-75-30 cells (0.5 ml; 2.5 × 104 cells/ml)
were added to the inside of the inserts and incubated for
3 h. After incubation, non-invading cells were removed
from the upper surface of the membrane using cotton-
tipped swabs. The cells on the lower surface of the mem-
brane were stained with Crystal violet and counted in the
central field of triplicate membranes.
TaqMan® Array human metastasis gene expression assays
and quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
TaqMan® Array Metastasis 96-Well Plates were obtained
from Life Technologies Corporation (California, USA) and
contained lyophilized TaqMan® Gene Expression Assays.
After converting total RNA to cDNA via reverse transcrip-
tion, TaqMan® Array Plates and the associated reagents
were used to quantitate mRNA expression levels. The re-
sults were analyzed using the RQ manager software.
Genes altered in the Taqman Array gene expression assays
were subsequently verified using a qRT-PCR assay system.
Total RNA was extracted using TRIzol reagent (Invitro-
gen). After converting total RNA to cDNA in a reverse
transcription (RT) reaction by Cdna Synthesis Kit (Cat.
6110A, TaKaRa, Dalian, China), qPCR were used to quan-
titate the mRNA expression levels by SYBR® Premix Ex
Taq™(Cat. RR420Q, TaKaRa). The cycling conditions were
as follows: 95°C for 5 minutes; 40 cycles of 95°C for 15 sec-
onds and 60°C for 32 seconds. GAPDH was used as an en-
dogenous control. Each qRT-PCR cycle was repeated
three times to confirm the results.
Dual luciferase reporter gene assays
Dual luciferase assays were performed as previously de-
scribed [21]. Luciferase activity was measured using the
dual luciferase reporter gene assay (Promega, USA), as
previously reported [20], and a SynergyHT Multi-Mode
Microplate Reader (BioTek, USA).
Statistical analysis
The experimental data are expressed as the mean ± stand-
ard deviation, and the statistical significance between the
different groups was determined using t-tests. The relation-
ship between CDK11 expression and the clinicopathologi-
cal features of breast cancer patients was analyzed using χ2and Fisher’s exact tests. All statistical tests were two sided,
and P values less than 0.05 were considered significant.Results
IHC analysis of CDK11 protein expression
We first evaluated CDK11 protein expression in 250 FFPE
breast cancer tissues and ANCTs. CDK11 was clearly
expressed in the nucleus in breast cancer tissues, and
CDK11 positive expression was found to be both at a
higher staining intensity and in a higher proportion of
positively stained cells (Figure 1A). Table 1 summarizes
Figure 2 CDK11p58 inhibits breast cancer cell metastasis in an ERα-dependent manner. (A) ZR-75-30 cells were transfected with wild-type
CDK11p58 (p58), kinase activated mutant (T370D), kinase dead mutant (T370A) or control vectors. After 6 h, Transwell assays were performed as
described. Crystal violet staining of invading cells is shown. Data are expressed as the mean ± SEM of the number of invading cells in more than
five separate areas. *P < 0.05 versus vector controls (n = 3 experiments). (B) MDA-MB-231 cells were transfected with CDK11p58 or various mutants.
After 6 h, Transwell assays were performed as described. Crystal violet staining of invading cells is shown. Data are expressed as the mean ± SEM
of the number of invading cells in more than five separate areas.
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logical features of breast cancer patients. CDK11 expression
was not correlated with the breast cancer patients’ meno-
pausal status, tumor size, HER-2 status, differentiation or
TNM status, but was negatively correlated with age, nodestatus, ER, relapse and metastasis status (P < 0.05). The pa-
tients with lower CDK11 expression tended to have a
higher risk of relapse and metastasis. All patients were
followed up for at least 8 years. Disease free survival (DFS)
was significantly worse in breast cancer patients with low
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dicate that low CDK11 expression in breast cancer is re-
lated to a worse prognosis.CDK11p58 inhibits ERα-positive breast cancer metastasis
As CDK11 expression was negatively correlated with node
status, relapse and metastasis status in breast cancer pa-
tients, we further investigated the role of CDK11p58 in the
migration and invasion of breast cancer by Transwell as-
says. Our previous study showed that the function of
CDK11p58 was kinase related, and we identified T370D as
a constantly activated CDK11p58 kinase mutant and
T370A as a kinase-dead mutant [13]. The invasion of ZR-
75-30 cells transfected with wild-type CDK11p58 and the
T370D mutant was significantly lower compared with the
control cells (P < 0.05; Figure 2A). In contrast, the kinase-
dead T370A mutant failed to suppress the metastasis of
ZR-75-30 cells. Notably, CDK11p58 failed to inhibit the mi-
gration and invasion of ER-negative MDA-MB-231 breast
cancer cells (Figure 2B). Together these data suggest thatFigure 3 CDK11p58 downregulates integrin β3 in ERα-positive breast
breast cancer cells. The expression of CDK11p58 was detected by qRT-PCR a
pathway in the TaqMan Array human metastasis gene expression assay. (C
human metastasis gene expression assay. (D) Validation of TaqMan Array hCDK11p58 inhibits ER-positive breast cancer metastasis in
a kinase-dependent manner.
Inhibition of metastasis by CDK11p58 is regulated through
integrin β3
To investigate the mechanism by which CDK11p58 in-
hibits metastasis, we used TaqMan Array human me-
tastasis expression plates to examine the expression of
key genes involved in cancer metastasis. MCF-7 cells
were transfected with CDK11p58, and the overexpres-
sion of CDK11p58 mRNA and protein was confirmed by
qRT-PCR and western blotting, respectively (Figure 3A).
We observed significant changes in the expression of nu-
merous metastasis-related genes in the CDK11p58-trans-
fected cells compared with control MCF-7 cells (Figure 3B
and C). Notably, integrin β3 was significantly repressed in
CDK11p58-transfected MCF-7 cells (Figure 3B), and these
results were further confirmed by qRT-PCR (Figure 3D).
Thus, we speculated that CDK11p58 might inhibit the
metastasis of breast cancer cells via the repression of
integrin β3.cancer cells. (A) Overexpression of CDK11p58 in MCF-7 ER-positive
nd western blotting. (B) Genes downregulated in the metastasis
) Genes upregulated in the metastasis pathway in the TaqMan Array
uman gene expression assays by qRT-PCR.
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As CDK11p58 inhibited the mRNA level of integrin β3,
we speculated that integrin β3 promoter activity was
regulated by CDK11p58. We cloned the ITGB3 promoter
(~2.5 kb) spanning -2000 to +50 from the transcriptional
start site into the pGL3-Basic (pGL3B) luciferase vector,
and transfected the vector into MCF-7 and ZR-75-30
cells for dual luciferase assays (Figure 4A and B). Cotrans-
fection of wild-type or T370D CDK11p58 vectors signifi-
cantly repressed ITGB3 promoter activity compared with
controls, whereas the T370A variant had no effect. These
data suggested that CDK11p58 inhibited the promoter ac-
tivity of integrin β3 in a kinase-dependent manner.
We then mapped the promoter region of integrin β3
to identify potential transcription factor binding sites
and found three potential estrogen response element
(ERE) consensus sites in the -1000 to -500 region. Thus,
we speculated that integrin β3 was regulated by ERα. To
test this hypothesis, pGL3-ITGB3 and ERα were co-
transfected into 293 T cells, and dual luciferase assay
results showed that ERα could increase the integrin β3
promoter activity (Figure 4C). We previously demon-
strated that CDK11p58 represses the transcription activity
of ERα. Therefore, we considered that CDK11p58 may re-
press integrin β3 promoter activity through ERα signaling.
To further determine whether the inhibition of integrin β3
by CDK11p58 is ERα dependent, we performed dual lucif-
erase assays in the MDA-MB-231 ERα-negative cell line.
As expected, CDK11p58 showed no effect on the integrin
β3 promoter in MDA-MB-231 cells (Figure 4D). TogetherFigure 4 CDK11p58 inhibits ITGB3 promoter activity in MCF-7 and ZR
kinase-dependent manner. Dual luciferase assays were performed in ZR-75-
(n = 3 experiments). (C) 293 T cells were transfected with the indicated plasm
cells were transfected with the indicated plasmids and luciferase assays werethese data suggest that CDK11p58 inhibits integrin β3
through ERα signaling.
We then examined this inhibition at the protein level.
We first performed CDK11p58 knockdown in ZR-75-30
cells using three siRNAs. The third siRNA was the most
efficient in knocking down CDK11p58 and was used for
subsequent experiments (Figure 5A). Western blotting re-
vealed that the overexpression of CDK11p58 attenuated in-
tegrin β3 expression, whereas siRNA-mediated knockdown
of CDK11p58 had no effect to attenuate integrin β3 expres-
sion (Figure 5B). Targeted knockdown of ERα by siRNA
led to the inhibition of integrin β3 expression, whereas ac-
tivation of ERα signaling by 17b-estradiol (E2) stimulated
integrin β3 expression (Figure 5C and D). The T370D mu-
tant significantly repressed ERα and integrin β3 protein
levels, while the T370A mutant failed to repress ERα and
integrin β3 protein levels (Figure 5E). Metastasis-related
matrix metalloproteinases (MMPs), including MMP2,
MMP3 and MMP9, were also repressed by CDK11p58 in a
kinase-dependent manner. Together these data indicated
that CDK11p58 represses integrin β3 expression to in-
hibit the metastasis of breast cancer via the regulation
of ERα signaling.
Discussion
CDK11p58 is involved in a variety of important regulatory
pathways in eukaryotic cells, including cell cycle control,
apoptosis, neuronal physiology, differentiation and tran-
scription [26-28]. CDK11p58 is a Ser/Thr kinase, and the
majority of its functions are dependent on its kinase-75-30 cells. (A and B) CDK11p58 inhibits ITGB3 promoter activity in a
30 and MCF-7 cells as described in Methods. P < 0.05 vs. controls
ids, and luciferase assays were performed 48 h later. (D) MDA-MB-231
performed 48 h later.
Figure 5 CDK11p58 inhibits cell motility and invasion in ERα-positive breast cancer cells through integrin β3. (A) ZR-75-30 cells were
transfected with specific siRNAs targeting CDK11p58. After 48 h, the cells were harvested and subject to immunoblotting analysis as indicated.
Protein levels were normalized to GAPDH. (B) ZR-75-30 cells were transfected with the CDK11p58 plasmid or siRNA3 targeting CDK11p58 as
indicated, and lysates were subjected to an immunoblotting analysis. (C) ZR-75-30 cells were transfected with siRNA targeting ERα, and after 48 h,
cell lysates were subjected to immunoblotting analysis. (D) ZR-75-30 cells were transfected with ERα, and after 36 h, the cells were treated with
ethanol or 10 nM E2 for an additional 12 h. The cells were harvested and subjected to immunoblotting analysis as indicated. (E) ZR-75-30 cells
were transfected with CDK11p58 wild-type or mutants. After 48 h, the cells were harvested and the lysates subjected to immunoblotting analysis
as indicated.
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inhibited ERα transcriptional activity by promoting its
degradation via the ubiquitin-proteasome pathway. In the
present study, we demonstrate, for the first time, that
CDK11p58 expression is involved in the negative regulation
of breast cancer invasion in a kinase-dependent manner.
Recent studies have reported the existence of various
genomic alterations of 1p36 in ERα-positive breast can-
cers. CDK11p58 is located on chromosome 1p36 and
plays a role in the negative regulation of ERα signaling.
Approximately 70–75% of breast cancers express ER
and/or progesterone receptor. In recent years, we have
witnessed tremendous advances in the understanding
of ERα biology, revealing a complex process of ERα sig-
naling that includes interactions with other signaling
pathways [29]. The ERα signaling pathway plays an im-
portant role in the development and progression of
breast cancer, and we previously showed that CDK11p58interacts with ERα in breast cancer cells. Estrogens and
ERα act as promoters of cell movement in different tis-
sues, including breast tissue [30]. Previous studies
showed that ERα induced breast cancer cell migration
and invasion via the phosphorylation of FAK and N-
WASP [24]. Another report revealed that within the
broader range of actions of ERα, rapid extra-nuclear
signaling to the actin cytoskeleton through the Gα13/
RhoA/ROCK/moesin cascade is relevant for the deter-
mination of estrogen-dependent breast cancer cell
movement and invasion, which are related to cancer
metastasis [31]. Previous studies also demonstrated
that the MAPK-integrated signaling crosstalk between
Ras and ERα leads to increased breast cancer invasion
[32]. Because CDK11p58 plays a negative role in the
regulation of ERα, we speculated that CDK11p58 may
participate in the progression of breast cancer via the
regulation of the ERα pathway.
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breast cancer patients and found that high expression of
CDK11 indicated a better prognosis, while low expres-
sion of CDK11 was related with a worse breast cancer
node status, relapse and metastasis. These data suggest
that CDK11p58 is related to migration and invasion. As
expected, CDK11p58 inhibited the migration and inva-
sion of ZR-75-30 ERα-positive breast cancer cells in a
kinase-dependent manner. To examine the mechanism
by which CDK11p58 inhibited breast cancer cell invasion,
we specifically examined CDK11p58-dependent gene ex-
pression changes in invasion signaling pathways using
TaqMan array human metastasis plates. We observed that
the expression of integrin β3 was significantly attenuated
in CDK11p58-transfected cells. Integrins are cell surface
glycoproteins that control cell attachment to the extracel-
lular matrix [33]. Integrins play a role in mammary gland
biology, with expression in all cell types within the gland
[34], and activate intracellular signaling pathways that
control proliferation, differentiation, apoptosis, cell motil-
ity, migration and survival [35,36]. Integrin β3 is expressed
on the surface of endothelial cells, smooth muscle cells,
monocytes and platelets [37]. Expression is predominantly
associated with tumor metastasis and has been reported
to increase the metastatic potential of melanoma, breast
cancer and lymphoma cells. Interestingly, the opposite ef-
fect is observed in ovarian cancer [38].
In this study, we found that integrin β3 promoter activ-
ity was significantly repressed by CDK11p58 and that this
repression was dependent on CDK11p58 kinase activity.
ERα belongs to the superfamily of nuclear receptors, com-
prising structurally conserved transcription factors that
enhance the transcription of specific genes upon hormone
binding [39]. Upon E2 binding, ERα specifically interacts
with ERE sequences in target promoters and stimulates
the transcription of a variety of E2-responsive genes [40].
As previously published, CDK11p58 is capable of repres-
sing the transcriptional activity of ERα and promotes its
degradation. In the present study, we further demonstrate
that the promoter activity of integrin β3 is stimulated by
ERα and that the inhibition of integrin β3 by CDK11p58 is
dependent on ERα.
Decreased expression of ERα correlated with a decrease
in integrin β3 protein. Furthermore, the induction of ERα
expression following transfection with ERα plasmids or
the activation of ERα signaling with E2 was correlated
with the enhanced expression of integrin β3 protein. Over-
all, CDK11p58 and T370D were capable of repressing the
expression and transactivation of ERα and ultimately inhi-
biting the expression of integrin β3, thereby inhibiting the
invasion of breast cancer cells. The kinase-dead mutants
T370A failed to inhibit the expression of ERα and integrin
β3, and were incapable of inhibiting cancer invasion.
Taken together, we conclude that CDK11p58 may inhibitbreast cancer cell invasion via the inhibition of the ERα
signaling pathway, leading to the inhibition of integrin
β3. Furthermore, metastasis-promoting MMP2, MMP3
and MMP9 proteins were subsequently inhibited. Thus,
CDK11p58 inhibits the invasion and metastasis of breast
cancer via the inhibition of integrin β3.
Conclusions
Our data show that CDK11p58 inhibits the invasion of
ERα-positive breast cancer cells by repressing integrin β3.
Thus, we demonstrate, for the first time, that CDK11p58 is
involved in the negative regulation of breast cancer inva-
sion in a kinase activity-dependent manner.
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